Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer

Breast cancer is a heterogeneous disease. Tamoxifen is frequently used to treat ER-positive breast cancer. Our team has identified a novel splice variant of NCOR2, BQ323636.1 (BQ), that mediates tamoxifen resistance. However, the upstream factors that modulate BQ expression are not apparent. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsoi, Ho, Tsang, Wai-Chung, Man, Ellen P. S., Leung, Man-Hong, You, Chan-Ping, Chan, Sum-Yin, Chan, Wing-Lok, Khoo, Ui-Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604393/
https://www.ncbi.nlm.nih.gov/pubmed/36293165
http://dx.doi.org/10.3390/ijms232012290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604393/
https://www.ncbi.nlm.nih.gov/pubmed/36293165
http://dx.doi.org/10.3390/ijms232012290

Ejemplares similares